Last Updated: 2026

Axonics Modulation Tech

Rank#3233

Market Cap3.63B

CountryUnited States

Summary

Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct salesforce and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.

History

Axonics Modulation Technologies Inc. was founded in 2013 to develop a unique implantable device for sacral neuromodulation therapies — using radio frequency delivered through an implantable pulse generator. In 2019, Axonics was the first to receive premarket approval (PMA) from the FDA for a rechargeable implantable neuromodulation device. The approval allowed Axonics to provide its bladder and bowel control offering on a broader scale in the U.S. and worldwide.

Mission

Our mission is to raise the standard of care in neuromodulation therapies by providing superior technology, superior outcomes and superior service.

Vision

Our vision is to make the world a healthier and better place by providing innovations in medicine that can help those who suffer from chronic conditions.

References

https://in.investing.com/equities/axonics-modulation-technologies

https://finance.yahoo.com/quote/AXNX/profile?p=AXNX

https://www.comparably.com/companies/axonics-modulation-technologies

https://www.crunchbase.com/organization/axonics-modulation-technologies

https://sec.report/CIK/0001603756

https://companiesmarketcap.com/

https://www.axonics.com

Leadership team

Mr. Raymond W. Cohen (CEO & Director)

Mr. Danny L. Dearen (Pres & CFO)

Mr. Rinda K. Sama (Chief Operating Officer)

Products / Services

Health Diagnostics, Medical, Medical Device

Number of Employees

500 - 1000

Address

Irvine, California, United States

Established

2012-01-01

Company Registration

SEC CIK number: 0001603756

Revenue

100M - 500M

Traded as

AXNX

Website

https://www.axonics.com

Social Media

Last Updated: 2026

Axonics Modulation Tech

Rank#3233

Market Cap3.63B

CountryUnited States

Summary

History

Mission

Our mission is to raise the standard of care in neuromodulation therapies by providing superior technology, superior outcomes and superior service.

Vision

Our vision is to make the world a healthier and better place by providing innovations in medicine that can help those who suffer from chronic conditions.

References

https://in.investing.com/equities/axonics-modulation-technologies

https://finance.yahoo.com/quote/AXNX/profile?p=AXNX

https://www.comparably.com/companies/axonics-modulation-technologies

https://www.crunchbase.com/organization/axonics-modulation-technologies

https://sec.report/CIK/0001603756

https://companiesmarketcap.com/

https://www.axonics.com

Leadership team

Mr. Raymond W. Cohen (CEO & Director)

Mr. Danny L. Dearen (Pres & CFO)

Mr. Rinda K. Sama (Chief Operating Officer)